Aarti Pharmalabs Ratios

Aarti Pharmalabs Ltd Ratios

The Aarti Pharmalabs Ltd Ratios page provides a complete fundamental analysis of Aarti Pharmalabs Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Aarti Pharmalabs Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Aarti Pharmalabs Ltd (NSE: AARTIPHARM, BSE: 543748) is currently trading at ₹681.20, with a market capitalization of ₹62.15B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Aarti Pharmalabs Ltd remains a key stock for fundamental analysis using Aarti Pharmalabs Ltd Ratios.

Aarti Pharmalabs Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Aarti Pharmalabs Ltd P/E ratio currently stands at 24.92, making it one of the most tracked metrics in Aarti Pharmalabs Ltd Ratios.

Historically, the Aarti Pharmalabs Ltd P/E ratio has shown strong fluctuations:

• 2024: 24.92
• 2023: 18.18
• 2022: 12.86
• 2021: 0
• 2020: 0

The rising Aarti Pharmalabs Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Aarti Pharmalabs Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.41.

Historical P/B trend:

• 2024: 3.41
• 2023: 2.24
• 2022: 1.60
• 2021: 0

Aarti Pharmalabs Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Aarti Pharmalabs Ltd P/S ratio currently stands at 3.25, an important part of Aarti Pharmalabs Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 3.25
• 2023: 2.17
• 2022: 1.28
• 2021: 0

The rising Aarti Pharmalabs Ltd P/S ratio indicates improved revenue valuation by investors.

Aarti Pharmalabs Ltd Price to Cash Flow Ratio (P/CF)

The Aarti Pharmalabs Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 21.61.

Historical Aarti Pharmalabs Ltd Price to Cash Flow Ratio:

• 2024: 21.61
• 2023: 19.50
• 2022: 10.82
• 2021: 0
• 2020: 0

The rising Aarti Pharmalabs Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Aarti Pharmalabs Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Aarti Pharmalabs Ltd EV currently stands at ₹71.46B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 71.46B
• 2023: 41.33B
• 2022: 26.41B
• 2021: 0

Aarti Pharmalabs Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Aarti Pharmalabs Ltd EV/EBITDA ratio is currently 16.17, a key metric in Aarti Pharmalabs Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 16.17
• 2023: 11.65
• 2022: 7.86
• 2021: 0

Higher Aarti Pharmalabs Ltd EV/EBITDA suggests premium valuation.

Aarti Pharmalabs Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Aarti Pharmalabs Ltd D/E ratio is currently 0.21, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.21
• 2023: 0.16
• 2022: 0.14
• 2021: 0.25

Aarti Pharmalabs Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Aarti Pharmalabs Ltd ROE currently stands at 14.54%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 14.54
• 2023: 13.08
• 2022: 13.14
• 2021: 17.63

Aarti Pharmalabs Ltd maintains stable profitability levels.

Aarti Pharmalabs Ltd Ratios Analysis Summary

The Aarti Pharmalabs Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Aarti Pharmalabs Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Aarti Pharmalabs Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.